Cell-Mediated Immunity in Multiple Sclerosis Patients Who Discontinued Therapy with an Integrin Inhibitor

Cover Page

Cite item

Full Text

Abstract

Introduction. Natalizumab (NTZ) is a humanized monoclonal antibody (mAb) that selectively inhibits α4-integrin adhesion molecule located on the surface of lymphocytes and prevents their trafficking into the central nervous system (CNS).

The aim of this study was to identify characteristics of lymphocyte population and subpopulation pattern in the peripheral blood (PB) of multiple sclerosis (MS) patients who discontinued NTZ due to an increased risk of developing developing progressive multifocal leukoencephalopathy.

Materials and methods. We conducted an open-label prospective observational study in 26 MS patients. Of those, 6 patients had rapidly progressive MS, 10 patients discontinued NTZ and had confirmed relapses afterwards, and 10 patients received NTZ and had no relapses during the washout period. Ten apparently healthy individuals were used as controls. Cell-mediated immunity parameters were evaluated by flow cytometry using a panel of mAbs to differentiation antigens of PB lymphocytes.

Results. Patients who discontinued NTZ had significantly decreased absolute lymphocyte counts in PB, decreased T-cytotoxic, NKT and B1 lymphocyte subpopulation levels, and decreased activated T-cell (CD3+HLA–DR+) levels, which may be related to their redistribution, passing through the blood-brain barrier, and trafficking into the central nervous system. CD20+ В-cell levels did not differ from normal. Additional immune predictors of MS relapses after NTZ discontinuation can include decreased absolute count of PB lymphocytes and decreased percentage of CD3+CD8+ T-cell, NKT-cell, and B1-cell (CD19+CD5+) subpopulations. Significantly increased levels of CD25+- and CD38+-activated B-cells compared with the normal levels in naïve patients and subjects without relapses after NTZ discontinuation may suggest a high activation potential of the circulating B-cell pool and, therefore, a high risk of MS relapses.

Conclusions. The changes in the lymphocyte subpopulation pattern in the PB of MS patients after NTZ discontinuation may have a prognostic value for assessing the risk of relapses; they justified switching patients to anti-B-cell therapy.

About the authors

Yuliana A. Belova

M.F. Vladimirsky Moscow Regional Research and Clinical Institute

Email: kotovsv@yandex.ru
ORCID iD: 0000-0003-1509-9608

Cand. Sci. (Biol.), senior researcher, Neurological department

Russian Federation, Moscow

Yulia Yu. Chuksina

M.F. Vladimirsky Moscow Regional Research and Clinical Institute

Email: kotovsv@yandex.ru
ORCID iD: 0000-0002-4393-1759

Cand. Sci. (Med.), senior researcher, Laboratory of biomedical research methods

Russian Federation, Moscow

Sergey V. Kotov

M.F. Vladimirsky Moscow Regional Research and Clinical Institute

Author for correspondence.
Email: kotovsv@yandex.ru
ORCID iD: 0000-0002-8706-7317

D. Sci. (Med.), Professor, Head, Department of neurology, Faculty of Advanced Training for Doctors, chief researcher, Neurological department

Russian Federation, Moscow

Irina A. Vasilenko

M.F. Vladimirsky Moscow Regional Research and Clinical Institute

Email: kotovsv@yandex.ru
ORCID iD: 0000-0002-6374-9786

D. Sci. (Med.), Professor, Head, Laboratory of biomedical research methods

Russian Federation, Moscow

References

  1. Baecher-Allan C., Kaskow B.J., Weiner H.L. Multiple sclerosis: mechanisms and immunotherapy. Neuron. 2018;97(4):742–768. doi: 10.1016/j.neuron.2018.01.021
  2. Danikowski K.M., Jayaraman S., Prabhakar B.S. Regulatory T cells in multiple sclerosis and myasthenia gravis. J. Neuroinflamm. 2017;14(1):117. doi: 10.1186/s12974-017-0892-8
  3. Cencioni M.T., Mattoscio M., Magliozzi R. et al. B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies. Nat. Rev. Neurol. 2021;17(7):399–414. doi: 10.1038/s41582-021-00498-5
  4. Хачанова Н.В. Высокоактивный рассеянный склероз — возможности выбора терапии моноклональными антителами. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(10, вып. 2):49–57. Khachanova N.V. Highly active multiple sclerosis: options for monoclonal antibody therapy. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2019;119(10, iss. 2):49–57. doi: 10.17116/jnevro201911910249
  5. Журавлева М.В., Давыдовская М.В., Лучинина Е.В. и др. Сравнение клинических преимуществ препаратов второй линии, изменяющих течение рассеянного склероза. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(8):148–153. Zhuravleva M.V., Davydovskaya M.V., Luchinina E.V. et al. Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2020;120(8):148–153. doi: 10.17116/jnevro2020120081148
  6. Khoy K., Mariotte D., Defer G. et al. Natalizumab in multiple sclerosis treatment: from biological effects to immune monitoring. Front. Immunol. 2020;11:549842. doi: 10.3389/fimmu.2020.549842
  7. Cobo-Calvo Á., Figueras A., Bau L. et al. Leukocyte adhesion molecule dynamics after Natalizumab withdrawal in Multiple Sclerosis. Clin. Immunol. 2016;171:18–24. doi: 10.1016/j.clim.2016.08.003
  8. Белова А.Н., Растеряева М.В., Жулина Н.И. и др. Воспалительный синдром восстановления иммунитета и ребаунд-синдром при отмене некоторых препаратов иммуномодулирующей терапии рассеянного склероза: общие представления и собственное наблюдение. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2017;117(2-2):74–84. Belova A.N., Rasteryaeva M.V., Zhulina N.I. et al. Immune reconstitution inflammatory syndrome and rebound syndrome in multiple sclerosis patients who stopped disease modification therapy: current understanding and a case report. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2017;117(2-2):74–84. (In Russ.)]. doi: 10.17116/jnevro20171172274-84
  9. Miravalle A., Jensen R., Kinkel R.P. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch. Neurol. 2011;68(2):186–191. doi: 10.1001/archneurol.2010.257
  10. Proschmann U., Inojosa H., Akgün K., Ziemssen T. Natalizumab pharmacokinetics and -dynamics and serum neurofilament in patients with multiple sclerosis. Front. Neurol. 2021;12:650530. doi: 10.3389/fneur.2021.650530
  11. Giovannoni G., Marta M., Davis A. et al. Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. Pract. Neurol. 2016;16(5):389–93. doi: 10.1136/practneurol-2015-001355
  12. Sellner J., Rommer P.S. A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis. Autoimmun. Rev. 2019;18(3):255–261. doi: 10.1016/j.autrev.2018.09.012
  13. Planas R., Jelčić I., Schippling S. et al. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur. J. Immunol. 2012;42(3):790–798. doi: 10.1002/eji.201142108
  14. Plavina T., Muralidharan K.K., Kuesters G. et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology. 2017;89(15): 1584–1593. doi: 10.1212/WNL.0000000000004485
  15. Мельников М.В., Пащенков М.В., Бойко А.Н. Дендритные клетки при рассеянном склерозе. Журнал неврологии и психиатрии им. С.С. Корса- кова. Спецвыпуски. 2017;117(2-2):22–30. Mel'nikov M.V., Pashchenkov M.V., Boiko A.N. Dendritic cells in multiple sclerosis. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2017;117(2-2):22-30. doi: 10.17116/jnevro20171172222-30
  16. Stüve O. The effects of natalizumab on the innate and adaptive immune system in the central nervous system. J. Neurol. Sci. 2008;274(1-2):39–41. doi: 10.1016/j.jns.2008.03.022
  17. Ядгаров М.Я., Кузовлев А.Н., Берикашвили Л.Б. и др. Важность оценки закона распределения данных: теория и практическое руководство. Анестезиология и реаниматология. 2021;(2):136–142. Yadgarov M.Ya., Kuzovlev A.N., Berikashvili L.B. et al. Importance of data distribution normality test: theory and practical guide. Russian Journal of Anaesthesiology and Reanimatology. 2021;(2):136–142. doi: 10.17116/anaesthesiology2021021136
  18. Наркевич А.Н., Виноградов К.А., Гржибовский А.М. Множественные сравнения в биомедицинских исследованиях: проблема и способы решения. Экология человека. 2020;10:55–64. Narkevich A.N., Vinogra- dov K.A., Grjibovski A.M. Multiple comparisons in biomedical research: the problem and its solutions. Human Ecology. 2020;10:55–64. doi: 10.33396/1728-0869-2020-10-55-64
  19. Arneth B. Activated CD4+ and CD8+ T cell proportions in multiple sclerosis patients. Inflammation. 2016;39(6):2040–2044. doi: 10.1007/s10753-016-0441-0
  20. Kaskow B.J., Baecher-Allan C. Effector T cells in multiple sclerosis. Cold Spring Harb. Perspect. Med. 2018;8(4):a029025. doi: 10.1101/cshperspect.a029025
  21. Wagner C.A., Roqué P.J., Mileur T.R. et al. Myelin-specific CD8+ T cells exacerbate brain inflammation in CNS autoimmunity. J. Clin. Invest. 2020;130(1):203–213. doi: 10.1172/JCI132531
  22. Liu R., Du S., Zhao L. et al. Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target. Front. Immunol. 2022;13:996469. doi: 10.3389/fimmu.2022.996469
  23. Poppell M., Hammel G., Ren Y. Immune regulatory functions of macrophages and microglia in central nervous system diseases. Int. J. Mol. Sci. 2023;24(6):5925. doi: 10.3390/ijms24065925
  24. Ломакин Я.А., Овчинникова Л.А., Захарова М.Н. и др. Смещение репертуара генов зародышевой линии в-клеточных рецепторов при рассеянном склерозе. Acta Naturae. 2022;14(4):84–93. Lomakin Ya.A., Ovchinnikova L.A., Zakharova M.N. et al. Multiple sclerosis is associated with immunoglobulin germline gene variation of transitional B cells. Acta Naturae. 2022;14(4):84–93. doi: 10.32607/actanaturae.11794

Copyright (c) 2024 Belova Y.A., Chuksina Y.Y., Kotov S.V., Vasilenko I.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies